Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Cartilage intermediate layer protein inhibits ligamentum flavum hypertrophy mediated by TGF-β1/SMAD3/SERPINE2 signaling pathway

doi: 10.1007/s00018-025-06051-7

Figure Lengend Snippet: CILP attenuates LF fibrosis via the TGF-β1/SMAD3/SERPINE2 axis. ( A ) A violin plot depicted differential SERPINE2 expression between Non-LFH and LFH groups (n = 6 per group), showing significant differences. ( B ) IHC of SERPINE2 in LF samples from Non-LFH and LFH groups (n = 6 per group). Scale bar: 50 µm. ( C , D ) Western blotting revealed elevated SERPINE2 protein levels between Non-LFH and LFH groups (n = 6 per group), with relative protein expression quantified. And mRNA concentration showed consistent results. ( E , F ) Western blotting demonstrated SERPINE2 expression in LF cells treated with TGF-β1 at 0, 8, 16, and 24 h time points, with relative protein expression quantified. And mRNA concentration showed consistent results. ( G ) Western blotting assessed protein expression levels of CILP, Collagen I, p-SMAD3, and α-SMA in LF cells subjected to various SERPINE2 treatments. ( H ) qRT-PCR assessed transcriptional profiles of CILP, ACTA2 (α-SMA), and COL1A2 across experimental conditions in LF cells. ( I ) WB analysis evaluated p-SMAD3 and fibrotic protein levels 48 hours post-transfection with CILP-overexpressing plasmids under different conditions in LF cells. ( J ) WB analysis examined p-SMAD3 and fibrotic protein expression 48 hours post-transfection with CILP-silencing plasmids under various regimens. Significance levels are denoted as follows: ns, not significant;* P < 0.05;** P < 0.01;*** P < 0.01

Article Snippet: In further experiments, cells were exposed to varying concentrations of CILP protein (10, 25, 50 ng/ml, RPC382Hu01, Cloud-Clone, TX, USA) and/or SERPINE2 protein (25 μg/ml, HY- P71085 , MCE) for 24 h. The plasmids and siRNA were obtained from Hanbio Biotechnology Co., Ltd, located in Shanghai, China.

Techniques: Expressing, Western Blot, Concentration Assay, Quantitative RT-PCR, Transfection

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Cartilage intermediate layer protein inhibits ligamentum flavum hypertrophy mediated by TGF-β1/SMAD3/SERPINE2 signaling pathway

doi: 10.1007/s00018-025-06051-7

Figure Lengend Snippet: CILP attenuates TGF-β1-mediated LFH in vivo. ( A - D ) IHC analysis of SERPINE2, TGF-β1, Collagen I, and p-SMAD3 in mouse tissues, with quantification of positive cell percentages. Scale bar: 50 µm. Significance levels are denoted as follows: ns, not significant;* P < 0.05; ** P < 0.01; *** P < 0.001

Article Snippet: In further experiments, cells were exposed to varying concentrations of CILP protein (10, 25, 50 ng/ml, RPC382Hu01, Cloud-Clone, TX, USA) and/or SERPINE2 protein (25 μg/ml, HY- P71085 , MCE) for 24 h. The plasmids and siRNA were obtained from Hanbio Biotechnology Co., Ltd, located in Shanghai, China.

Techniques: In Vivo

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: BMP6 as a therapeutic target for preeclampsia: enhancing trophoblast invasion and vascular mimicry

doi: 10.1007/s00018-025-06040-w

Figure Lengend Snippet: BMP6 signaling enhancement compensates for shallow trophoblast invasion in PE. An examination of clinical samples from PE patients and their gestational age-matched controls revealed that BMP6 was upregulated in preeclamptic placentas. BMP6 enhances trophoblast invasion via ID1-mediated upregulation of SERPINE2 and PlGF. Moreover, BMP6 also intensifies trophoblast vascular mimicry through the ID1-mediated upregulation of PlGF. Both canonical (p-SMAD1/5/9) and noncanonical (p-SMAD2/3) pathways participate in BMP6-induced ID1 expression. Our findings indicate that the increase in BMP6 signaling during late gestation could serve as a compensatory response to shallow trophoblast invasion in PE, which in light of BMP6 and its downstream targets could serve as diagnostic markers and therapeutic target applications in the clinical management of PE. This schematic diagram was created with Biorender.com

Article Snippet: SMAD1 (D59D7) rabbit monoclonal antibody (#6944), phospho-SMAD1/5/9 (D5B10) rabbit monoclonal antibody (#13820), SMAD2 (D43B4) rabbit monoclonal antibody (#5339), phospho-SMAD2 (E8F3R) rabbit monoclonal antibody (#18338), SMAD3 (C67H9) rabbit monoclonal antibody (#9523), phospho-SMAD3 (C25A9) rabbit monoclonal antibody (# 9520), SMAD4 (D3R4N) rabbit monoclonal antibody (#46535), horseradish peroxidase (HRP)-linked anti-mouse IgG (#7076), and anti-rabbit IgG (#7074) were purchased from Cell Signaling Technology (Danvers, MA, USA); the mouse monoclonal antibody HLA-G (#11–499-C100) was purchased from EXBIO (Vestec, Czech Republic); CK7-specific rabbit polyclonal antibody (#17513-1-AP), BMP6 rabbit polyclonal antibody (#55421-1-AP), SERPINE2 rabbit polyclonal antibody (#11303-1-AP), and α-Tubulin mouse monoclonal antibody (#66031-1-Ig) were purchased from Proteintech (Wuhan, China); ID1 mouse monoclonal antibody (#sc-133104) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA); CD34 rabbit monoclonal antibody (#A19015) and α-SMA rabbit monoclonal antibody (#A2235) were obtained from ABclonal (Wuhan, China); Goat anti-Rabbit IgG secondary antibody, Alexa Fluor 594 (#A-11012) and goat anti-Mouse IgG secondary antibody, Alexa Fluor 488 (#A-11011) were purchased from Thermo Fisher (NY, USA).

Techniques: Expressing, Diagnostic Assay

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: BMP6 as a therapeutic target for preeclampsia: enhancing trophoblast invasion and vascular mimicry

doi: 10.1007/s00018-025-06040-w

Figure Lengend Snippet: ID1 mediates BMP6-induced SERPINE2 and PlGF upregulation in human trophoblasts. A-C , BMP6 upregulates SERPINE2 protein levels in trophoblasts. A , HTR8/SVneo cells were treated with different concentrations (0, 6.25, 12.5, 25, 50, or 100 ng/mL) of BMP6, and the SERPINE2 protein levels after 24 h of treatment were examined by Western blot analysis. The upper panel shows a representative Western blot image, and the lower panel shows the summarized quantitative results. B , SERPINE2 protein levels in HTR8/SVneo cells after treatment with vehicle (Ctrl) or 50 ng/mL BMP6 for different durations (24, 48, and 72 h). The upper panel shows a representative Western blot image, and the lower panel shows the summarized quantitative results. C , SERPINE2 protein levels in human primary EVTs. The left panel shows a representative Western blot image, and the right panel shows the summarized quantitative results. D-E , BMP6 promotes PlGF accumulation in the conditioned medium of trophoblasts. D , HTR8/SVneo cells were treated with or without 50 ng/mL BMP6 for 24–48 h. PlGF accumulation in conditioned medium was measured using ELISA. E , PlGF accumulation in conditioned medium was assayed by ELISA 48 h after BMP6 treatment in primary EVTs. F-J , ID1 mediates BMP6-induced SERPINE2 and PlGF upregulation in human trophoblasts. HTR8/SVneo cells were transfected for 48 h with 20 nM control non-targeting siRNA (si-Ctrl) or siRNA targeting ID1 (si- ID1 ) before treatment with or without 50 ng/mL BMP6. F , ID1 mRNA levels were examined by qPCR 6 h after BMP6 (50 ng/mL) treatment in HTR8/SVneo cells, with GAPDH used as the reference gene. G and H , SERPINE2 and ID1 protein levels in HTR8/SVneo cells ( G ) and human primary EVTs ( H ) after transfection with siRNA targeting ID1 , followed by treatment with or without BMP6 for 24 h, as assessed by Western blot. The left panel shows a representative Western blot image, and the right panel shows the summarized quantitative results. I , PGF mRNA levels were examined by qPCR 6 h after BMP6 treatment in HTR8/SVneo cells, with GAPDH used as the reference gene. J , PlGF accumulation in conditioned medium was assayed by ELISA 24 h after BMP6 treatment in HTR8/SVneo cells. K , SMAD4 mediates BMP6-induced upregulation of PlGF in human trophoblasts. HTR8/SVneo cells were transfected for 48 h with 20 nM control non-targeting siRNA (si-Ctrl) or siRNA targeting SMAD4 (si- SMAD4 ) before treatment with or without 50 ng/mL BMP6. PlGF accumulation in conditioned medium was assayed by ELISA 24 h after BMP6 treatment in HTR8/SVneo cells. The quantitative results are expressed as the means ± SEMs of at least three independent experiments. One-way ANOVA was used for analyses in A , and two-way ANOVA was used for comparisons in B-K . Groups without common letters are significantly different from each other ( P < 0.05). BMP6, bone morphogenetic protein 6; SERPINE2, serpin family E member 2; EVT, extravillous cytotrophoblast; Ctrl, control; PlGF, placental growth factor; ID1, inhibitor of DNA-binding 1

Article Snippet: SMAD1 (D59D7) rabbit monoclonal antibody (#6944), phospho-SMAD1/5/9 (D5B10) rabbit monoclonal antibody (#13820), SMAD2 (D43B4) rabbit monoclonal antibody (#5339), phospho-SMAD2 (E8F3R) rabbit monoclonal antibody (#18338), SMAD3 (C67H9) rabbit monoclonal antibody (#9523), phospho-SMAD3 (C25A9) rabbit monoclonal antibody (# 9520), SMAD4 (D3R4N) rabbit monoclonal antibody (#46535), horseradish peroxidase (HRP)-linked anti-mouse IgG (#7076), and anti-rabbit IgG (#7074) were purchased from Cell Signaling Technology (Danvers, MA, USA); the mouse monoclonal antibody HLA-G (#11–499-C100) was purchased from EXBIO (Vestec, Czech Republic); CK7-specific rabbit polyclonal antibody (#17513-1-AP), BMP6 rabbit polyclonal antibody (#55421-1-AP), SERPINE2 rabbit polyclonal antibody (#11303-1-AP), and α-Tubulin mouse monoclonal antibody (#66031-1-Ig) were purchased from Proteintech (Wuhan, China); ID1 mouse monoclonal antibody (#sc-133104) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA); CD34 rabbit monoclonal antibody (#A19015) and α-SMA rabbit monoclonal antibody (#A2235) were obtained from ABclonal (Wuhan, China); Goat anti-Rabbit IgG secondary antibody, Alexa Fluor 594 (#A-11012) and goat anti-Mouse IgG secondary antibody, Alexa Fluor 488 (#A-11011) were purchased from Thermo Fisher (NY, USA).

Techniques: Western Blot, Enzyme-linked Immunosorbent Assay, Transfection, Control, Binding Assay

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: BMP6 as a therapeutic target for preeclampsia: enhancing trophoblast invasion and vascular mimicry

doi: 10.1007/s00018-025-06040-w

Figure Lengend Snippet: Both SERPINE2 and PlGF mediate BMP6-induced trophoblast invasion. A-J , HTR8/SVneo cells or primary EVTs were transfected for 48 h with 20 nM control nontargeting siRNA (si-Ctrl), 20 nM siRNA targeting SERPINE2 (si- SERPINE2 ) or PGF (si- PGF ) before treatment with or without 50 ng/mL BMP6 for 24 h. A and B , The protein levels of SERPINE2 in HTR8/SVneo cells ( A ) and human primary EVTs ( B ) after 24 h of BMP6 treatment. The upper panel shows a representative Western blot image, and the lower panel shows the summarized quantitative results. C , PlGF accumulation in conditioned medium with or without BMP6 treatment for 24 h was assayed by ELISA in HTR8/SVneo cells. D , PGF mRNA levels in human primary EVTs with or without BMP6 treatment for 6 h were examined by RT‒qPCR, with GAPDH as the reference gene. E - H , Transwell assays were employed to examine the invasiveness of HTR8/SVneo cells ( E and G ) and primary EVTs ( F and H ) with or without BMP6 treatment for 36 h. I and J , Endothelial-like tube formation assays were used to assess vascular mimicry of HTR8/SVneo cells with or without BMP6 treatment for 12 h. Representative images from the endothelial-like tube formation assay are displayed in the above panel; the summarized quantitative results are displayed in the lower panel. Scale bar, 100 μm. The quantitative results are expressed as the means ± SEMs of at least three independent experiments. Two-way ANOVA was used for data comparison. Groups without common letters are significantly different from each other ( P < 0.05). BMP6, bone morphogenetic protein 6; SERPINE2, serpin family E member 2; PGF, placental growth factor; Ctrl, control; EVT, extravillous cytotrophoblast

Article Snippet: SMAD1 (D59D7) rabbit monoclonal antibody (#6944), phospho-SMAD1/5/9 (D5B10) rabbit monoclonal antibody (#13820), SMAD2 (D43B4) rabbit monoclonal antibody (#5339), phospho-SMAD2 (E8F3R) rabbit monoclonal antibody (#18338), SMAD3 (C67H9) rabbit monoclonal antibody (#9523), phospho-SMAD3 (C25A9) rabbit monoclonal antibody (# 9520), SMAD4 (D3R4N) rabbit monoclonal antibody (#46535), horseradish peroxidase (HRP)-linked anti-mouse IgG (#7076), and anti-rabbit IgG (#7074) were purchased from Cell Signaling Technology (Danvers, MA, USA); the mouse monoclonal antibody HLA-G (#11–499-C100) was purchased from EXBIO (Vestec, Czech Republic); CK7-specific rabbit polyclonal antibody (#17513-1-AP), BMP6 rabbit polyclonal antibody (#55421-1-AP), SERPINE2 rabbit polyclonal antibody (#11303-1-AP), and α-Tubulin mouse monoclonal antibody (#66031-1-Ig) were purchased from Proteintech (Wuhan, China); ID1 mouse monoclonal antibody (#sc-133104) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA); CD34 rabbit monoclonal antibody (#A19015) and α-SMA rabbit monoclonal antibody (#A2235) were obtained from ABclonal (Wuhan, China); Goat anti-Rabbit IgG secondary antibody, Alexa Fluor 594 (#A-11012) and goat anti-Mouse IgG secondary antibody, Alexa Fluor 488 (#A-11011) were purchased from Thermo Fisher (NY, USA).

Techniques: Transfection, Control, Western Blot, Enzyme-linked Immunosorbent Assay, Tube Formation Assay, Comparison

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: BMP6 as a therapeutic target for preeclampsia: enhancing trophoblast invasion and vascular mimicry

doi: 10.1007/s00018-025-06040-w

Figure Lengend Snippet: BMP6 is elevated in patients with PE and in PE model rats. A-C , BMP6 is elevated in patients with PE. A , RT‒qPCR analysis of BMP6 mRNA expression levels in the placentas of control women ( n = 10) and PE patients ( n = 10), with GAPDH as the reference gene. B , Western blot analysis of BMP6 protein expression levels in the placentas of control women ( n = 4) and PE patients ( n = 4). C , Spearman correlation analysis between the placental BMP6 mRNA levels and the value of log10 (SBP) of the corresponding patients. The gray area represents the 95% CI. Each dot represents one sample. D , The animal experimental protocol. E and F , BMP6 is elevated in the plasma of PE model rats. Rat plasma levels of BMP6 ( E ) and PlGF ( F ) in the Ad Fc + PBS group ( n = 4) and Ad Flt1 + PBS group ( n = 4). G-M , BMP6 is elevated in the placenta of PE model rats at G13. RNA-seq analysis of rat placentas at G13 in the Ad Fc + PBS group ( n = 3) and Ad Flt1 + PBS group ( n = 3). G , Heatmap depicting DEGs in the two groups. H , Dot plots of significantly enriched GO terms; the dot size represents the number of DEGs associated with a particular GO term. I , KEGG hierarchical network plot of pathways. J , GSEA-KEGG Ridge plot of pathways. K , GSEA plots of cytokine-cytokine receptor interaction pathway. L , Volcano plot of RNA-seq data showing DEGs between the Ad Fc + PBS group and the Ad Flt1 + PBS group. M , Circos graph displaying the coexpression networks of five genes in rat placenta samples. Each sector of the circle represents one gene, and its width indicates the total amount of co-occurrence that connects one gene to the other. The width of each link represents the total number of coexpressed genes among the linked genes. Student’s t-test was used for comparisons between two groups in A , B , E , and F . Groups without common letters are significantly different from each other ( P < 0.05). SD, Sprague–Dawley; BMP6, bone morphogenetic protein 6; PlGF, placental growth factor; PBS, phosphate-buffered saline; Ad Flt1, adenovirus expressing fms-like tyrosine kinase-1; Ad Fc, adenovirus-expressing control IgG2a Fc fragment; FC, fold change; Serpine2, serpin family E member 2; Id1, inhibitor of DNA-binding 1

Article Snippet: SMAD1 (D59D7) rabbit monoclonal antibody (#6944), phospho-SMAD1/5/9 (D5B10) rabbit monoclonal antibody (#13820), SMAD2 (D43B4) rabbit monoclonal antibody (#5339), phospho-SMAD2 (E8F3R) rabbit monoclonal antibody (#18338), SMAD3 (C67H9) rabbit monoclonal antibody (#9523), phospho-SMAD3 (C25A9) rabbit monoclonal antibody (# 9520), SMAD4 (D3R4N) rabbit monoclonal antibody (#46535), horseradish peroxidase (HRP)-linked anti-mouse IgG (#7076), and anti-rabbit IgG (#7074) were purchased from Cell Signaling Technology (Danvers, MA, USA); the mouse monoclonal antibody HLA-G (#11–499-C100) was purchased from EXBIO (Vestec, Czech Republic); CK7-specific rabbit polyclonal antibody (#17513-1-AP), BMP6 rabbit polyclonal antibody (#55421-1-AP), SERPINE2 rabbit polyclonal antibody (#11303-1-AP), and α-Tubulin mouse monoclonal antibody (#66031-1-Ig) were purchased from Proteintech (Wuhan, China); ID1 mouse monoclonal antibody (#sc-133104) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA); CD34 rabbit monoclonal antibody (#A19015) and α-SMA rabbit monoclonal antibody (#A2235) were obtained from ABclonal (Wuhan, China); Goat anti-Rabbit IgG secondary antibody, Alexa Fluor 594 (#A-11012) and goat anti-Mouse IgG secondary antibody, Alexa Fluor 488 (#A-11011) were purchased from Thermo Fisher (NY, USA).

Techniques: Expressing, Control, Western Blot, Clinical Proteomics, RNA Sequencing, Saline, Binding Assay

Journal: Diabetes Therapy

Article Title: Elevated Serum SERPINE2 Levels are Linked to Impaired Renal Function in Patients with Type 2 Diabetes Mellitus

doi: 10.1007/s13300-025-01742-7

Figure Lengend Snippet: Serum serpin peptidase inhibitor clade E member 2 (SERPINE2) levels were compared between control subjects and patients with type 2 diabetes mellitus (T2DM). a Serum SERPINE2 levels in control subjects and patients with T2DM were detected by enzyme-linked immunosorbent assay (ELISA). The serum SERPINE2 concentration in patients with T2DM ( n = 292) was significantly higher than that in control subjects ( n = 120). Student t test was applied. b Comparison of serum SERPINE2 levels in patients with T2DM with normoalbuminuria, microalbuminuria, and macroalbuminuria. ANOVA was applied. *** P < 0.001

Article Snippet: Serum biomarker levels in control subjects and patients with T2DM were measured using ELISA kits for NGAL (QK1757, R&D Systems), KIM-1 (DSKM100, R&D Systems), TGFβ1 (DY240, R&D Systems), CTGF (DY9190-05, R&D Systems), and antibodies against SERPINE2 (AF2980, R&D Systems) [ ].

Techniques: Control, Enzyme-linked Immunosorbent Assay, Concentration Assay, Comparison

Journal: Diabetes Therapy

Article Title: Elevated Serum SERPINE2 Levels are Linked to Impaired Renal Function in Patients with Type 2 Diabetes Mellitus

doi: 10.1007/s13300-025-01742-7

Figure Lengend Snippet: Correlation between serum serpin peptidase inhibitor clade E member 2 (SERPINE2) and clinical indicators. Pearson correlation test was performed between SERPINE2 with a estimated glomerular filtration rate (eGFR), b serum creatinine (Scr), c neutrophil gelatinase-associated lipocalin (NGAL), d kidney injury molecule 1 (KIM-1), e transforming growth factor-β1 (TGFβ1), and f connective tissue growth factor (CTGF) in all patients with type 2 diabetes mellitus (T2DM)

Article Snippet: Serum biomarker levels in control subjects and patients with T2DM were measured using ELISA kits for NGAL (QK1757, R&D Systems), KIM-1 (DSKM100, R&D Systems), TGFβ1 (DY240, R&D Systems), CTGF (DY9190-05, R&D Systems), and antibodies against SERPINE2 (AF2980, R&D Systems) [ ].

Techniques: Filtration

Journal: Diabetes Therapy

Article Title: Elevated Serum SERPINE2 Levels are Linked to Impaired Renal Function in Patients with Type 2 Diabetes Mellitus

doi: 10.1007/s13300-025-01742-7

Figure Lengend Snippet: Receiver operating characteristic (ROC) curve was used to obtain the optimal cutoff value of serum serpin peptidase inhibitor clade E member 2 (SERPINE2) (278.94 pg/mL) that distinguishes the patients with type 2 diabetes mellitus (T2DM) with and without albuminuria. AUC area under the curve

Article Snippet: Serum biomarker levels in control subjects and patients with T2DM were measured using ELISA kits for NGAL (QK1757, R&D Systems), KIM-1 (DSKM100, R&D Systems), TGFβ1 (DY240, R&D Systems), CTGF (DY9190-05, R&D Systems), and antibodies against SERPINE2 (AF2980, R&D Systems) [ ].

Techniques:

Journal: Diabetes Therapy

Article Title: Elevated Serum SERPINE2 Levels are Linked to Impaired Renal Function in Patients with Type 2 Diabetes Mellitus

doi: 10.1007/s13300-025-01742-7

Figure Lengend Snippet: Schematic diagram of serpin peptidase inhibitor clade E member 2 (SERPINE2) in the development of diabetic nephropathy. Increased SERPINE2 in patients with type 2 diabetes mellitus (T2DM) with renal dysfunction promotes podocyte injury and albuminuria. SERPINE2 also enhances renal fibrosis by promoting fibrosis-related cytokines, such as transforming growth factor-β1 (TGFβ1) and connective tissue growth factor (CTGF). Therefore, the increase in SERPINE2 levels plays an aggravating role in injury of glomerular and tubular cells caused by hyperglycemia and advanced glycation end products (AGEs)

Article Snippet: Serum biomarker levels in control subjects and patients with T2DM were measured using ELISA kits for NGAL (QK1757, R&D Systems), KIM-1 (DSKM100, R&D Systems), TGFβ1 (DY240, R&D Systems), CTGF (DY9190-05, R&D Systems), and antibodies against SERPINE2 (AF2980, R&D Systems) [ ].

Techniques:

Journal: Oncotarget

Article Title: Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages

doi: 10.18632/oncotarget.12927

Figure Lengend Snippet: ( A ) Masson trichrome staining performed on 4T1 Ctrl and shSerpine2 tumors. Representative images show increased collagen encapsulation (blue) of SerpinE2 KD tumors. Scale bar100μm. ( B - C ) Intravital imaging using (IVI-MP) of 4T1 Ctrl and shSerpine2 tumors. (B) Representative images show collagen I fibers detected by the SHG signal (cyan) at the surface of 4T1 tumors; scale bar25μm. (C) Average SHG signal intensity was determined per 100μm z-stack; data are acquired from 19-30 separate z-stacks from 3 mice per cell line. * P < 0.00036. D. IVI-MP performed on mice bearing GFP-labeled 4T1 control and shSerpinE2 tumors. Representative images show GFP-labeled tumor cells (green), phagocytic dextran positive cells (red); SHG imaging identified collagen I fibers (cyan). Scale bars25μm. (E-F) ( E ) GFP-labeled 4T1 tumor-bearing mice were treated with control liposomes or clodronate-containing liposomes until IVI-MP was performed. Representative images are shown as in (D). ( F ) Quantification of SHG (cyan) signal intensity in 100 μm Z-stacks of tumors in treated animals. Data are mean ± SEM of measurements from 40-61 Z-stacks from at least 3 different tumors for each treatment group. * P < 0.016. All data are mean ± SEM.

Article Snippet: Anti-human SerpinE2 Ab (MAB2980) was from R&D systems.

Techniques: Staining, Encapsulation, Imaging, Labeling, Control, Liposomes

Journal: Oncotarget

Article Title: Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages

doi: 10.18632/oncotarget.12927

Figure Lengend Snippet: Conditioned medium (CM) from 4T1 and 168FARN ( A ) or MDA-MB435 ( B ) cultures was incubated overnight with Ab11, then bound serpinE2 was pulled-down with Protein G, and analyzed by western blot with the rodent-specific antibody, 4B3 (A), or a human-specific antibody (B). (A) The right panel shows a short exposure of serpinE2 complexes from 4T1 CM, but none in 168FARN CM (long exposure on the left), as well as an IP of the preformed tPA/serpinE2 complex. ( C ) SFM loaded with purified human serpinE2 or the preformed serpinE2/tPA complex was IP'd with Ab11 as in (A) & (B) and analyzed by western blot with a human serpinE2-specific antibody. The serpinE2 complex and uncomplexed serpinE2 are indicated with arrowheads.

Article Snippet: Anti-human SerpinE2 Ab (MAB2980) was from R&D systems.

Techniques: Incubation, Western Blot, Purification

Journal: Oncotarget

Article Title: Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages

doi: 10.18632/oncotarget.12927

Figure Lengend Snippet: The LRP1 receptor is expressed on tumor cells and on macrophages and we propose that serpinE2 targeting with Ab11 impacts on LRP1 signaling in both cell types. ( A ) In metastatic tumors, serpinE2-LRP1 binding stimulates ERK signaling and secretion of CCL2. Tumor cells display hyperactivation of receptor tyrosine kinases (RTKs); FGFRs, which are active in the 4T1 model, also stimulate ERK pathway activation. We speculate that in macrophages, the combination of high CCL2 levels and serpinE2-activated LRP1 promotes the M2 phenotype. Indeed, there are high levels of phagocytic, Texas-red positive M2 tumor associated macrophages (TAMs) in the metastatic tumors; they are known to be responsible for degrading the matrix during tumor development. ( B ) Ab11 or sepinE2 KD (not drawn in model) lowers ERK pathway activity and the secretion of CCL2, and stimulates TIMP1 secretion. Tyrosine kinase inhibitors (TKIs) block RTK signaling. The matrix-degrading M2 TAMs are decreased in Ab11-treated tumors. Moreover, depleting macrophages with clodronate liposomes results in deposition of a dense collagen matrix, similar to that observed in Ab11-treated tumors. Thus, we propose that the drop in CCL2, which contributes to a decrease in M2 TAMs, as well as blocking serpinE2, which skews the TAMs towards the M1 phenotype, causes the emergence of a dense collagen matrix that inhibits intravasation and metastatic dissemination.

Article Snippet: Anti-human SerpinE2 Ab (MAB2980) was from R&D systems.

Techniques: Binding Assay, Activation Assay, Activity Assay, Blocking Assay, Liposomes

Journal: JCI insight

Article Title: Transcriptional heterogeneity of fibroblasts is a hallmark of the aging heart.

doi: 10.1172/jci.insight.131092

Figure Lengend Snippet: Figure 6. Age-dependent changes of fibroblast function on endothelial cells. (A and B) Experimental outline and tube formation assay of human umbilical vein endothelial cells (HUVECs) that were cultured in conditioned medium received from young (12 weeks) and aged (20 months) cardiac mouse fibroblasts. Accumulated tube length was measured in 5 randomly chosen microscopic fields with a computer-assisted microscope using Axiovision 4.5 (Zeiss) (scale bar: 100 μm; n = 4). (C) Capillary density of random healthy areas of young (12 weeks; n = 6) and old (n = 8) heart sections versus capillary density of fibrotic (n = 8) areas of aged hearts (20 months). Shown is the quantification of the Isolectin B4–positive area versus the total area (%). (D) Expression of Serpine1, Serpine2, and Efemp1 in fibroblasts displayed in log scale in trajectory plots. (E) Secretion of SerpinE1 in isolated young and aged cardiac fibroblasts cultured for 24 hours in serum-free medium. Data were derived using a mouse angiogenesis array (R&D Systems) of culture supernatants of isolated cardiac fibroblasts (n = 4). (F) Tube formation assay of HUVECs that were cultured in conditioned medium received from young (12 weeks) and aged (20 months) cardiac mouse fibroblasts. The aged phenotype was rescued by supplementing the aged fibroblast medium with 4 μg of an anti-Serpin antibody. Accumulated tube length was mea- sured in 5 randomly chosen microscopic fields with a computer-assisted microscope using Axiovision 4.5 (Zeiss) (scale bar: 200 μm; n = 4). (G) RNA expression

Article Snippet: For the recombinant serpin study, HUVECs were cultured in medium supplemented with 10 ng/mL serpin E1 (CSB-EP021081MO, Cusabio) or serpin E2 (2175-PI-010, R&D Systems) for 24 hours.

Techniques: Tube Formation Assay, Cell Culture, Microscopy, Expressing, Isolation, Derivative Assay, RNA Expression